Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Adaptimmune Ther ADR
(NQ:
ADAP
)
1.210
+0.040 (+3.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adaptimmune Ther ADR
< Previous
1
2
3
4
5
6
Next >
ADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 12, 2024
ADAP stock results show that Adaptimmune Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Adaptimmune Reports Q2 2024 Financial and Business Updates
August 12, 2024
Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumorPatients can...
Via
Newsfile
Exposures
Product Safety
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
August 12, 2024
Via
Benzinga
The Latest Analyst Ratings For Adaptimmune Therapeutics
August 05, 2024
Via
Benzinga
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
August 02, 2024
FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S.,...
Via
Benzinga
Exposures
Product Safety
Why Adaptimmune Therapeutics (ADAP) Stock Is Moving
May 31, 2024
Adaptimmune Therapeutics shares are trading higher by 15.8% during Friday's session. The company and Galapagos entered a clinical collaboration.
Via
Benzinga
Adaptimmune Therapeutics Earnings Preview
March 05, 2024
Via
Benzinga
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
August 01, 2024
From
Adaptimmune Therapeutics plc
Via
Business Wire
3 Biotech Moonshots With Imminent Catalyst Potential
July 03, 2024
Biotech has been one of the most explosive sectors. Better, further upside is likely, thanks to some of the top biotech stocks with catalysts.
Via
InvestorPlace
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
June 03, 2024
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response...
Via
Newsfile
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
May 31, 2024
Via
AB Newswire
Exposures
Product Safety
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 31, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 31, 2024
Via
Benzinga
Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
May 31, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 31, 2024
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers on Friday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
May 30, 2024
Via
Benzinga
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
May 30, 2024
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell...
Via
Newsfile
ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 15, 2024
ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Adaptimmune Reports Q1 2024 Financial and Business Updates
May 15, 2024
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date...
Via
Newsfile
Exposures
Product Safety
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
May 15, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
May 01, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
April 19, 2024
Via
Benzinga
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
April 12, 2024
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader...
Via
Newsfile
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
March 27, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
March 08, 2024
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 08, 2024
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
Via
Benzinga
ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 06, 2024
ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
March 06, 2024
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date...
Via
Newsfile
Topics
Economy
Exposures
Product Safety
Supply Chain
Earnings Scheduled For March 6, 2024
March 06, 2024
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
Via
Benzinga
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
February 27, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.